In this edition:
ENGOT-ov65/KEYNOTE-B96: pembrolizumab + weekly paclitaxel ± bevacizumab in PROC
AtTEnd: final OS results
ICON8B: final OS results
REJOICE-Ovarian01: dose-optimisation of R-DXd in PROC
First-line camrelizumab + famitinib vs. platinum-based chemotherapy in cervical cancer
FONTANA: AZD5335 (an FRα-targeted ADC) in PROC
NAPISTAR 1-01: TUB-040 (homogenous DAR8 ADC targeting Napi2b) in PROC
DUO-O/ENGOT-ov46/GOG-3025: final OS results
DICE: weekly paclitaxel + TAK228 (dual mTORC1/2 inhibitor) in epithelial ovarian/fallopian tube cancer
ROSELLA: relacorilant + nab-paclitaxel in PARPi-exposed PROC
Please login below to download this issue (PDF)